RxDoctor Payments Data

Britney Palekar

Family · Lewes, DENPI 1881144061

Payments from drug & device makers

$1,017in general payments, 2019–2025

Across 11 payments — averaging $92.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$304
  • Amgen$223
  • Dexcom, Inc.$129
  • Biohaven Pharmaceuticals, Inc.$93
  • Boehringer Ingelheim$77
  • Lilly USA, LLC$71
  • plus $119 from 2 others

What the payments were for

  • Food & beverage$1,017100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,017 in reported general payments places this provider in the 65th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$96,597
Medicare patients
295
Services billed
1,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$65,372
JardianceEmpagliflozin25$34,359
MounjaroTirzepatide13$21,115
Rosuvastatin Calcium207$4,327
Atorvastatin Calcium336$4,141
Ezetimibe62$2,503
Levothyroxine Sodium225$2,248
Omeprazole114$2,010
Duloxetine Hcl51$1,742
Losartan Potassium145$1,711
Esomeprazole Magnesium30$1,528
SynthroidLevothyroxine Sodium46$1,465
Albuterol Sulfate HfaAlbuterol Sulfate54$1,456
Lisinopril234$1,442
Metoprolol Succinate82$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$77$34,35925 claims
Lilly USA, LLCMounjaro$71$21,11513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 523 family providers in Delaware.

Other family in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →